Re-Examination Board affirms validity of Teva’s Copaxone patent07 Nov 2022Devin DoyleTeva’s 802 Patent claims a dosing regimen for treating multiple sclerosis with Copaxone (glatiramer acetate). The Federal Court held the 802 Patent...Read More
